CytomX Therapeutics Profit Margin 2014-2022 | CTMX
Current and historical gross margin, operating margin and net profit margin for CytomX Therapeutics (CTMX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. CytomX Therapeutics net profit margin as of September 30, 2022 is -135.65%.
|CytomX Therapeutics Annual Profit Margins
|CytomX Therapeutics Quarterly Profit Margins
||Medical - Biomedical and Genetics
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.